InvestorsHub Logo
Followers 62
Posts 3990
Boards Moderated 0
Alias Born 05/25/2021

Re: jondoeuk post# 343

Monday, 07/24/2023 11:02:09 PM

Monday, July 24, 2023 11:02:09 PM

Post# of 550
NVCR retailers should be very careful. The CEO has emptied 94% of his position and made over $240m among which $160m was made after the publication of the first paper on the blinded results of p3 DCVax-L clinical trial on May 29 2018. Take a specific look at what he did after the JAMA paper was published on November 17, 2022. Did he sense something? Does it look like he still holds confidence in the company?

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVCR News